Cannabinoids are a collection of chemicals that come from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and research has said it has anti-inflammatory effects when induced on animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals that gives off a psychotropic effect in animals brains.
Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to bind and work in the body. This paper will look at the therapeutic potential of cannabinoids so they can be used in a clinical setting.
Here is the full scientific article if you wish to download it.
Here are the main points of the study:
The FDA approved a product weilding synthetic THC (dronabinol) in the 1980’s for the mediation of nausea and vomiting in cancer patients getting chemotherapy treatment. The 1990’s saw cannabinoids being introduced as an appetite fueler for people with HIV and this has furtherly intensified the studies in the cannabinoid chemicals.
The last 30 years have witnessed extensive research in the field of cannabinoids and their therapeutic potential. A lot of progress has been made because of synthetic cannabis being cultivated. The CB1 and CB2 cannabinoid receptors were discovered, which spurred on a massive amount of biological effects on the human body. A big hurdle still exists in that the knowledge of the structural parameters responsible for isolating the outlawed psychotropic effects from the noticeable useful pharmacological effects, which could result in nonpsychoactive therapeutic drugs.
Already, the UK medical industry has created a drug that contains synthetic cannabinoids in order to treat patients who suffer from epilepsy. This alone is very promising for the cannabis plant and shows that it does contain therapeutic effects. However, the side effects still need to be looked at.